Matteo Lambertini, MD, PhD, on Atezolizumab in Triple-Negative Breast Cancer

Posted: Monday, July 15, 2019

Now that an atezolizumab-containing regimen has been approved for eligible patients with advanced triple-negative breast cancer, what are some of the investigational approaches being explored with this agent in earlier-stage disease?